UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors

    • Categories

    Archives

    Jun

    06

    UCB Hosts HRH Princess Astrid and Belgian Economic Mission at Atlanta Campus

    Today, UCB was pleased to host Her Royal Highness Princess Astrid of Belgium (HRH), Belgian dignitaries, and Belgian business leaders to visit our U.S. headquarters in Atlanta, Georgia.

    Read More Share:linkedin| twitter| email| facebook

    Jun

    01

    Life with MG & What I Wish For Everyone Who is Diagnosed

    Read More Share:linkedin| twitter| email| facebook

    May

    27

    My Commitment to the Newly Diagnosed and All People Living with Myasthenia Gravis

    Read More Share:linkedin| twitter| email| facebook

    May

    23

    UCB Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to be Presented at EULAR 2022

    Read More Share:linkedin| twitter| email| facebook

    May

    23

    First Presentations of Phase 3 Data for Bimekizumab Across the Full Spectrum of Axial Spondyloarthritis to be Shared at EULAR 2022

    Read More Share:linkedin| twitter| email| facebook

    May

    12

    Recognizing the Less Common, but Equally Burdensome, Forms of Arthritis During Arthritis Awareness Month

    Read More Share:linkedin| twitter| email| facebook

    May

    10

    Recognizing our Rising Star and Luminary: Kerry Black and Brooke Fleming Recognized by the Healthcare Businesswomen’s Association

    UCB congratulates Kerry Black, Head of Early Solutions U.S. Operations, and Brooke Fleming, Head of Omnichannel Marketing and Digital Enablement, for their recognition by the Healthcare Businesswomen's Association (HBA) as 2022 Luminary and Rising Star, respectively. 

    Read More Share:linkedin| twitter| email| facebook

    May

    10

    UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis

    Read More Share:linkedin| twitter| email| facebook

    Mar

    28

    FINTEPLA® (fenfluramine) Oral Solution Now FDA Approved for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)

    Read More Share:linkedin| twitter| email| facebook

    Mar

    26

    New Long-Term Complete Skin Clearance Data for Bimekizumab in Moderate to Severe Plaque Psoriasis Presented at the 2022 AAD Annual Meeting

    Read More Share:linkedin| twitter| email| facebook

    © 2009 - 2025 UCB, Inc. Atlanta. All rights reserved. 
    Last updated: August 2025